TuHURA Biosciences enters its May 22 earnings event in an uncomfortable position: the stock is down 27% over the past month to $2.31, short sellers hold nearly a quarter of the free float, and the borrow market has been volatile enough to punish anyone slow to cover.
Short interest is the dominant tension here. At 23.9% of the free float — using ORTEX's free-float-adjusted calculation — the short position is heavy for a micro-cap biotech with a binary clinical readout approaching. That figure has eased modestly from its recent peak of 25.6% on May 6, and shares short have fallen about 7% from a week ago, suggesting some shorts trimmed heading into the event. Still, the absolute level has climbed roughly two percentage points since early April, when it ran near 21–22% of the float. This is not a position that has been aggressively unwound.
The borrow market adds another layer of pressure. Cost to borrow peaked at 21.5% annualised as recently as May 11 before cooling to 15.1% by May 14 — a move that tells you conditions loosened slightly but remain expensive relative to the broad market. Availability — the ratio of shares still available to borrow against shares already lent out — points to a tight lending pool, with borrow utilisation running at 86%, well off its 52-week high of 94.6% but still leaving limited slack. Anyone wanting to establish a new short position this week is paying a premium for the privilege.
The ORTEX short score reinforces the signal. At 85.8, it ranks in the top few percentile of all names in the universe for short-side conviction — and it has crept higher through the week, up from 81.5 at the start of May. Two covering analysts carry Buy ratings with mean price targets around $8–9, a level roughly four times the current price. Citizens initiated coverage on April 27 with a Market Outperform and a $9 target, the most recent formal action. HC Wainwright has reiterated Buy multiple times, most recently holding a $10 target. The bull case centres on the personalized cancer vaccine IFx-2.0, which received FDA Orphan Drug Designation and showed a 50% response rate in anti-PD1 refractory melanoma patients. Bears point to the absence of approved therapies, ongoing cash burn, and a Phase 3 top-line readout not expected until Q1 2027 — leaving investors staring at a long runway of dilution risk.
Price history at events provides context without comfort. The last two corporate announcements produced day-one moves of -4.9% and -6.4% respectively, with five-day drawdowns of -25.4% and -14.7%. The one outlier was November 2025, when the stock gained 19.2% on the day and 26.2% over the following five sessions. That asymmetry — two painful prints, one sharp rally — reflects how binary these catalysts are for early-stage oncology names.
Institutional ownership offers one counterpoint to the short pressure. The top two holders, Vijay Patel and Matthew Nachtrab, added a combined 6 million shares through April, lifting their stakes to 19.3% and 6.4% of shares outstanding respectively. BlackRock added 364,000 shares over the same period. That insider-adjacent buying at the register does not negate the short thesis, but it does mean a meaningful chunk of the float is sitting with holders who recently increased — not trimmed — their exposure.
With the May 22 event now six days away, the key data point to watch is whether short interest continues to ease or re-builds in the final days before the release.
See the live data behind this article on ORTEX.
Open HURA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
